Baxter Q3 revenue up 3%; non-GAAP EPS up 37%; updates guidance

• Baxter International (NYSE:BAX +0.5%) Q3 results: Revenues: $2,558M (+2.9%); Renal: $977M (+3.6%); Hospital Products: $1,581M (+2.4%); Operating Income: $186M (+102.2%); Net Income: $127M; EPS: $0.23; Non-GAAP EPS: $0.56 (+36.6%); Quick Assets: $240M (-4.4%); CF Ops: $183M (-18.3%).
• 2016 Guidance: Sales Growth: ~2% on reported basis; EPS before special items: $1.88 - 1.91.
• Q4 Guidance: Sales Growth: ~2% on reported basis; EPS before special items: $0.49 - 0.52.
• Shares up 3% premarket.